Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Genaro Gutierrez

Interventional Pain Medicine Austin, TX Medical Doctor

NPI 1396971826 CMS profile 1311629

4316 James Casey St, Bldg B, Suite 200, Austin, TX 78745

Open in the dashboard

General payments

$124,855

951 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,153,489 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Genaro Gutierrez of Austin, TX is reported in the CMS Open Payments database as having received $124,855 across 951 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,153,489 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,897 67
2024 General $12,869 137
2023 General $32,237 207
2022 General $35,614 260
2021 General $10,715 140
2020 General $11,689 43
2019 General $13,835 97

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Genaro Gutierrez
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Genaro Gutierrez were reported at $7,897. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Genaro Gutierrez Interventional Pain Medicine median Middle half National median
2019 $13,835 $684 $216–$2,079 $163
2020 $11,689 $382 $122–$1,109 $114
2021 $10,715 $552 $167–$1,554 $132
2022 $35,614 $605 $187–$1,924 $149
2023 $32,237 $671 $195–$1,915 $160
2024 $12,869 $684 $206–$1,837 $164
2025 $7,897 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. SPR Therapeutics, Inc $66,580 121 payments
  2. Boston Scientific Corporation $25,707 156 payments
  3. Abbott Laboratories $8,520 256 payments
  4. SI-BONE, Inc. $7,785 30 payments
  5. Nalu Medical, Inc. $4,928 44 payments
  6. Medtronic, Inc. $2,674 98 payments
  7. BIOTRONIK NRO, Inc. $2,280 30 payments
  8. Relievant Medsystems, Inc. $1,424 24 payments
  9. Nevro Corp. $860 16 payments
  10. Vertiflex, Inc. $551 11 payments
  11. Other $3,546 165 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $55,850 27 payments
  2. Food and Beverage $35,890 882 payments
  3. Travel and Lodging $13,592 31 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,775 8 payments
  5. Charitable Contribution $4,900 1 payment
  6. Compensation for serving as faculty or as a speaker for a medical education program $1,800 1 payment
  7. Education $47 1 payment
Products named General payments · program years 2019–2025
  1. SPRINT PNS System $66,580 121 payments
  2. SPECTRA WAVEWRITER $12,861 18 payments
  3. IFUSE IMPLANT $7,594 26 payments
  4. General - Therapies $6,061 17 payments
  5. Nalu Neurostimulation System $4,928 44 payments
  6. PROCLAIM $2,639 91 payments
  7. OCTRODE $2,191 71 payments
  8. Prospera $2,107 20 payments
  9. WaveWriter Alpha Prime 16 $1,653 5 payments
  10. INTELLIS ADAPTIVESTIM $1,642 69 payments
  11. Other $18,196 479 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

2,606

Median for Pain Management: 951

Drug cost

$85,557

Median for Pain Management: $26,034

Branded share of claims

53.3%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 993 $27,230
Belbuca Buprenorphine Hcl Brand 16 $13,051
Nucynta Tapentadol Hcl Brand 14 $11,897
Oxycontin Oxycodone Hcl Brand 19 $5,977
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 194 $5,401
Morphine Sulfate Er Morphine Sulfate Brand 91 $3,055
Lidocaine Generic 23 $3,037
Oxycodone Hcl Generic 158 $2,620
Gabapentin Generic 245 $2,593
Pregabalin Generic 122 $2,345

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 62 billing codes

Paid by Medicare

$161,072

Of which drugs: $465

Medicare patients

377

Average age 74

Services billed

5,139

250 women, 127 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 36%
Depression 36%
Diabetes 28%
Osteoporosis 23%
Atrial fibrillation 20%
Chronic kidney disease 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 50 3,643 $389

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BELBUCA
$35 16 —
NURTEC ODT
$31 — —
ZAVZPRET
$31 — —
UBRELVY
$26 — —
Qutenza
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

951 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record